Indberetningsfrekvenserne for bekræftede og mistænkte tilfælde af rabdomyolyse i forbindelse med cerivastatinmonoterapi er større end for de øvrige statiner.
The reporting rates of confirmed and suspected cases of rhabdomyolysis in association with cerivastatin monotherapy is greater than that seen with any of the other statins.